文献速递神经免疫

多发性硬化3种组织病理学免疫病理模式对血液净化治疗反应的差异

Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项单中心队列研究纳入69例经脑活检分类为模式1、2、3的早期活动性多发性硬化患者,评估血液净化治疗的疗效。模式2患者功能应答率55%,模式3为0%(模式2 vs 3 P < .001);模式2获益最大,模式3可能无获益。

要点

  • 模式2患者功能应答率55%,模式3为0%(模式2 vs 3 P < .001)。
  • 模式1功能应答率31%,模式2为55%,模式3为0%。
  • 脑干受累为功能应答的负性预测因素(logOR,-1.43;95% CI,-3.21 to 0.17;P = .03)。

核心结论

  • 血液净化治疗反应与免疫病理模式相关:模式1和2患者临床改善,模式2获益最大,模式3患者似无获益。

研究设计与样本

  • 单中心队列研究,2005年至2016年在全国范围招募69例经脑活检分类为模式1、2或3的早期活动性炎性脱髓鞘患者。

主要发现

  • 功能应答:模式1 5/16例(31%),模式2 22/40例(55%),模式3 0/13例(0%)(模式2 vs 3 P < .001)。
  • 影像学改善:模式1 4例(25%),模式2 22例(56%),模式3 1例(11%)。
  • EDSS评分变化应答率:模式1 25%,模式2 40%,模式3 0%。
  • 脑干受累为功能应答负性预测因素(logOR,-1.43;95% CI,-3.21 to 0.17;P = .03)。
  • 免疫吸附相较血浆置换可能为阳性预测因素(logOR,3.26;95% CI,0.75 to 8.13;P = .01)。

临床怎么用

  • 作者认为血液净化治疗反应与免疫病理模式相关,模式2患者获益最大,模式3患者似无获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Plasma exchange and immunoadsorption are second-line apheresis therapies for patients experiencing multiple sclerosis relapses. Early active multiple sclerosis lesions can be classified into different histopathological patterns of demyelination. Pattern 1 and 2 lesions show T-cell- and macrophage-associated demyelination, and pattern 2 is selectively associated with immunoglobulin and complement deposits, suggesting a humoral immune response. Pattern 3 lesions show signs of oligodendrocyte degeneration. Thus it is possible that pathogenic heterogeneity might predict therapy response. OBJECTIVE: To evaluate the apheresis response in relation to histopathologically defined immunopathological patterns of multiple sclerosis. DESIGN, SETTING AND PARTICIPANTS: This single-center cohort study recruited 69 patients nationwide between 2005 and 2016. All included patients had a diagnosis of early active inflammatory demyelination consistent with multiple sclerosis; were classified into patterns 1, 2, or 3 based on brain biopsy analysis; and underwent apheresis treatments. Patients who had concomitant severe disease, neuromyelitis optica, or acute disseminated encephalomyelitis were excluded. MAIN OUTCOMES AND MEASURES: The primary therapy outcome was a functionally relevant improvement of the relapse-related neurological deficit. Radiological and Expanded Disability Status Scale changes were secondary outcome parameters. RESULTS: The mean (SD) age of patients was 36.6 (13.3) years; 46 of the 69 participants (67%) were female. Overall, 16 patients (23%) exhibited pattern 1 lesions, 40 (58%) had pattern 2 lesions, and 13 (19%) had pattern 3 lesions. A functional therapy response was observed in 5 of the 16 patients with pattern 1 disease (31%) and 22 of the 40 patients with pattern 2 disease (55%), but none of the 13 patients with pattern 3 disease exhibited improvement (pattern 2 vs 3 P < .001). Radiological improvements were found in 4 (25%), 22 (56%), and 1 (11%) of patients with patterns 1, 2, and 3, respectively. The respective rates of response measured by changes in Expanded Disability Status Scale scores were 25%, 40%, and 0%. Brainstem involvement was a negative predictive factor for the functional therapy response (logarithmic odds ratio [logOR], -1.43; 95% CI, -3.21 to 0.17; P = .03), while immunoadsorption (as compared with plasma exchange) might be a positive predictive factor (logOR, 3.26; 95% CI, 0.75 to 8.13; P = .01). CONCLUSIONS AND RELEVANCE: This cohort study provides evidence that the response to apheresis treatment is associated with immunopathological patterns. Patients with both patterns 1 and 2 improved clinically after apheresis treatment, but pattern 2 patients who showed signs of a humoral immune response benefited most. Apheresis appears unlikely to benefit patients with pattern 3 lesions.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Stork L, Ellenberger D, Beißbarth T, et al. Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. JAMA Neurol. 2018. PMID: 29404583. doi:10.1001/jamaneurol.2017.4842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。